Genflow Biosciences PLC (GENF) · 2026-10-05
Day 182 SIRT6c findings were directional and non-significant, while the pre-specified primary read is Day 320; Genflow selected intravenous pDNA as veterinary lead delivery modality.
Genflow Biosciences Plc (GENF) · 2026-09-08
Genflow's 24-dog SLAB trial met its primary endpoint, reducing biological age measured by the GRIM methylation clock, with treated animals showing improvement versus controls. Detailed results are due at the Animal Longevity Summit in October 2026.
Genflow Biosciences Plc (GENF) · 2026-09-07
Genflow Biosciences has appointed ON365 Partners Inc. as its investor relations adviser with immediate effect, replacing Harbor Access, which previously supported its investor relations activities.
Genflow Biosciences Plc (GENF) · 2026-08-03
Genflow Biosciences said US 2026/0199524 A1 was published and Track One examination granted for its foundational US SIRT6 application. Publication is not a patent grant.
Genflow Biosciences Plc (GENF) · 2026-07-13
Genflow said Gad Berdugo joined the Board as Independent Non-Executive Chairman in January, while the company also highlighted progress across its SLAB and glaucoma programmes. The update said the Acuitas collaboration is fully funded by Acuitas and non-dilutive, with no cash consideration payable by Genflow.
Genflow Biosciences Plc (GENF) · 2026-06-17
Genflow Biosciences will present SLAB clinical study data at Animal Longevity Summit 2026 in Toronto on 1-2 October 2026. The study began in March 2025 and ends in June 2026.